Healthcare has been the market’s best-performing sector during the past five years, with many stocks rising 200% or more. However, investors shouldn’t assume that the sector has been fully exploited. While many healthcare stocks have probably topped out for now, others still have room to run. For outsized gain potential in the coming years, consider a relatively small, but innovative, medical device company called Natus Medical, Inc. (Nasdaq: BABY). Shares of Natus have been on fire, thanks to success in the firm’s two main markets, neurology and newborn care. Yet the promise of more growth, with the help of several… Read More
Healthcare has been the market’s best-performing sector during the past five years, with many stocks rising 200% or more. However, investors shouldn’t assume that the sector has been fully exploited. While many healthcare stocks have probably topped out for now, others still have room to run. For outsized gain potential in the coming years, consider a relatively small, but innovative, medical device company called Natus Medical, Inc. (Nasdaq: BABY). Shares of Natus have been on fire, thanks to success in the firm’s two main markets, neurology and newborn care. Yet the promise of more growth, with the help of several encouraging new ventures, should propel Natus well beyond its current market value of $1.2 billion. Founded in 1989, Natus first made its mark in neurology by providing tests for the detection and monitoring of epilepsy, Alzheimer’s disease and many other neurological disorders. The firm offers multiple varieties of (and adjuncts to) three such tests: electroencephalography (EEG), electromyography (EMG) and polysomnography (PSG). In a key competitive advantage, these devices typically run on proprietary software or algorithms, which confer unique features, such as a seizure detection program that enables faster, more accurate EEG interpretation. Accuracy is further boosted by a… Read More